With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from ...

Scientists have developed a breakthrough therapy that could revolutionise the treatment of high cholesterol, which currently ...

A new DNA-based therapy could cut cholesterol nearly in half—without relying on statins or causing side effects.

Discover how cholesterol-lowering drug targets may reduce dementia risk through genetic insights. Keep reading.

Cardiologists often struggle to assess heart attack risk. New startups using AI could help.

Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented challenge to the US healthcare system. In a blog post, senior ...

Morning Report is The Hill’s a.m. newsletter. Subscribe here. In today’s issue: ▪ Inside the John Bolton indictment ▪ ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

An updated guideline on the management of dyslipidemias has been published by the European Society of Cardiology and European Atherosclerosis Society.